#	Pagina
attuale pagina	/open-h2020/projects/220263/index.html
-1	/open-consip/fornitori/2016/profilo-01674310121/index.html
-2	/open-consip/fornitori/2016/profilo-05685740721/index.html
-3	/open-consip/fornitori/2016/profilo-02469190751/index.html
-4	/open-consip/fornitori/2016/profilo-05696210821/index.html
-5	/open-consip/fornitori/2016/profilo-sm6539/index.html
-6	/open-consip/fornitori/2016/profilo-04526320751/index.html
-7	/open-consip/fornitori/2016/profilo-03425560541/index.html
-8	/open-consip/fornitori/2016/profilo-04055650404/index.html
-9	/open-consip/fornitori/2016/profilo-00997250113/index.html
-10	/open-consip/fornitori/2016/profilo-01949650855/index.html

Opendata, web and dolomites

CardioReGenix SIGNED

CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

CardioReGenix project word cloud

Explore the words cloud of the CardioReGenix project. It provides you a very rough idea of what is the project "CardioReGenix" about.

risk gene cellular monogenetic incremental first data technological bottlenecks cardiology treatments harnessing ema refine mechanisms rare expression platforms people gmp regulation preclinical conventional undertaking successfully translation disease cvd gain mainly who reducing overcome sme competitive million immune disciplinary therapeutic models authorization optimizing prospect man business strategy myocardial innovations cardiovascular vitro position vi significantly deaths impacted innovative involvement preliminary validate diseases atmp vectors atmps clinical adverse deeper momentum ischemia grade treating gained valorization strengthen generation liaising vii cardioregenix therapy vector efficient suffering latest treatment manufacturing progress marketing implementing die allowed worldwide 17 gains 31 heart molecular patients estimates maximizing cardiac safer

Project "CardioReGenix" data sheet

The following table provides information about the project.

Coordinator	VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 website: www.vub.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Total cost	14˙839˙773 €
EC max contribution	14˙839˙773 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2023-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VRIJE UNIVERSITEIT BRUSSEL VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 website: www.vub.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSEL)	coordinator	1˙987˙859.00
2	FINVECTOR OY FINVECTOR OY Organization address address: MICROKATU 1 S city: KUOPIO postcode: 70210 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (KUOPIO)	participant	1˙601˙405.00
3	ITA-SUOMEN YLIOPISTO ITA-SUOMEN YLIOPISTO Organization address address: YLIOPISTONRANTA 1 E city: KUOPIO postcode: 70211 website: www.uef.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (KUOPIO)	participant	1˙564˙156.00
4	CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL Organization address address: OLSHAUSENSTRASSE 40 city: KIEL postcode: 24118 website: http://www.uni-kiel.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (KIEL)	participant	1˙411˙526.00
5	THE UNIVERSITY OF EDINBURGH THE UNIVERSITY OF EDINBURGH Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL website: www.ed.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (EDINBURGH)	participant	1˙356˙501.00
6	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	1˙193˙622.00
7	STICHTING VUMC STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	1˙106˙750.00
8	KING'S COLLEGE LONDON KING'S COLLEGE LONDON Organization address address: STRAND city: LONDON postcode: WC2R 2LS website: www.kcl.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	1˙013˙675.00
9	CARDIOR PHARMACEUTICALS GMBH CARDIOR PHARMACEUTICALS GMBH Organization address address: FEODOR LYNEN STR 15 city: HANNOVER postcode: 30625 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	908˙249.00
10	POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA Organization address address: PL 100 city: KYS postcode: 70029 website: www.kuh.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (KYS)	participant	890˙640.00
11	BATAVIA BIOSCIENCES BV BATAVIA BIOSCIENCES BV Organization address address: ZERNIKEDREEF 16 city: LEIDEN postcode: 2333 CL website: www.bataviabioservices.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	776˙507.00
12	A2F ASSOCIATES LIMITED A2F ASSOCIATES LIMITED Organization address address: 7 LAUREATE PADDOCKS city: NEWMARKET postcode: CB8 0AP website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NEWMARKET)	participant	718˙845.00
13	ASPHALION SL ASPHALION SL Organization address address: CALLE TARRAGONA, NUMEROS 151-157, PLANTA 10, BLOQU city: BARCELONA postcode: 8014 website: www.asphalion.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	310˙035.00

Map

Project objective

WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted diseases such as CVD. Recent, deeper understanding of the molecular/cellular mechanisms of CVD and technology associated with more efficient and safer gene therapy vectors has allowed new opportunities for development of next-generation ATMPs for CVD. CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome bottlenecks in gene therapy for CVD by (i) maximizing cardiac-specific gene expression; (ii) maximizing cardiac-specific gene delivery; (iii) reducing adverse immune responses; (iv) optimizing manufacturing for research and clinical-grade ATMPs ; (v) validate new promising targets using in vitro and preclinical models; (vi) undertaking first-in-man studies; (vii) developing and implementing an exploitation and valorization strategy with strong EU SME involvement. CardioReGenix is a high risk/high gain project supported by robust preliminary data and multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. CardioReGenix will (i) strengthen Europe's competitive position in gene therapy development for CVD; (ii) improve the prospect of successfully treating patients suffering from CVD by gene therapy and (iii) develop and refine the latest gene therapy platforms that go significantly beyond the state of the art.

Publications

List of publications.
year	authors and title	journal	last update
2019	Dongchao Lu, Thomas Thum RNA-based diagnostic and therapeutic strategies for cardiovascular disease published pages: , ISSN: 1759-5002, DOI: 10.1038/s41569-019-0218-x	Nature Reviews Cardiology	2019-08-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOREGENIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOREGENIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More